In this study, the circulating miRNome from diagnostic neuroblastoma serum was assessed for identification of non-invasive biomarkers with potential in monitoring metastatic disease. After determining the circulating neuroblastoma miRNome, 743 miRNAs were screened in two independent cohorts of 131 and 54 patients. Evaluation of serum miRNA variance in a model testing for tumor stage, MYCN status, age at diagnosis and overall survival, revealed tumor stage as the most significant factor impacting miRNA abundance in neuroblastoma serum. Differential expression analysis between patients with metastatic and localized disease revealed 9 miRNAs strongly associated with metastatic stage 4 disease in both patient cohorts. Increasing levels of these miRNAs were also observed in serum from xenografted mice bearing human neuroblastoma tumors. Moreover, murine serum miRNA levels were strongly associated with tumor volume, suggesting this miRNA signature may be applied to monitor disease burden.
Introduction
Neuroblastoma is a childhood cancer arising from the developing sympathetic nervous system. [1] The disease is responsible for 11% of pediatric cancer deaths and is ranked third among cancers with the highest mortality rate. [2] Approximately 60% of the neuroblastoma patients are diagnosed with metastatic disease, mostly represented in the high-risk patient sub-group. High-risk patients have low survival rates of about 50%, and two thirds of these children will ultimately relapse, eventually entering a second line of intensive treatment, enrolling in an early-stage clinical trial or receiving palliative therapy. [1] Monitoring of treatment response is essential for assessment of its efficacy and for guiding the procedure of follow-up treatment after refractory or relapsed neuroblastoma.
Current methods for monitoring disease and evaluation of treatment response are mostly based on detection of minimal residual disease (MRD), which is determined by estimating the number of residual tumor cells in peripheral blood or bone marrow. [3] While several cellular MRD markers have been proposed, biomarkers for non-invasive cell-free determination of disease burden are currently lacking.
MicroRNAs, a class of small non-coding RNAs involved in various aspects of health and disease, including neuroblastoma pathophysiology, seem to be particularly stable and abundant in serum and plasma. [4, 5] Several studies have reported a relationship between serum miRNAs and disease characteristics such as MYCN amplification, or increased risk for adverse outcome. [6, 7] The interest in pursuing the investigation of the miRNome from liquid biopsy samples is also fortified by the fact that collection, processing and storage of these samples is relatively straightforward and less invasive.
For these reasons, the circulating miRNome may be a very valuable source for development of more advanced or refined tests for longitudinal treatment follow-up of neuroblastoma patients.
In the present study, we quantified the circulating miRNome from 185 diagnostic serum samples and assessed the association of four disease characteristics with serum miRNA abundance: the international neuroblastoma staging system (INSS), gene copy number status of the MYCN oncogene, age at diagnosis, and overall survival. We found a strong positive correlation between serum miRNA abundance and tumor stage and selected 9 miRNAs with a proportional increase with increasing tumor stage.
As tumor stage reflects cancer spread, we propose this set of miRNAs as serum markers for assessment of disease burden in human neuroblastoma.
Results

Defining the human neuroblastoma circulating miRNome
As only a subset of miRNAs end up in circulation, we decided to first define the circulating miRNome (i.e. the ensemble of miRNAs that are detectable in serum from NB patients). To this end, we created three serum pools, each composed of 5 patient samples ( Figure 1 ). Pooled samples were either high-risk patients that died of the disease (pool 1), high-risk patients that survived (pool 2) or low-risk patients that survived the disease (pool 3). We argue that these groups are representative for the majority of the neuroblastoma patient population, resulting in a comprehensive selection of circulating NB miRNAs. The pooled samples were screened for 1805 miRNAs. A set of 751 miRNAs, well expressed in at least one of the serum pools, was ultimately selected, hereby defining the NB miRNome. Expression of the NB miRNome was subsequently analyzed by RT-qPCR in 2 NB patient cohorts of 131 and 54 serum samples, respectively.
Before normalization, eight miRNAs with missing values in more than 75% of the samples were excluded from the dataset. All analyses were performed on the first cohort initially.
The second cohort was used to validate the findings from the first cohort.
Metastatic disease status has the largest impact on circulating miRNA levels in serum
Generalized additive modeling (GAM) was used on normalized miRNA expression values in order to quantify the association with tumor stage, MYCN status, age at diagnosis and overall survival. A straightforward model was chosen, whereby interaction terms were excluded, since our aim was to determine which of these features has the largest impact on serum miRNA expression and hence is responsible for the largest variance in the data set.
The analysis returned the level of significance (P-value) and the percentage of variance in the dataset explained by each of the tested features. The level of significance was used to measure the prediction ability of disease features for the 743 tested miRNAs. The percentage of variance was used to define the importance of each feature in influencing miRNA expression in serum. The average statistical significance, the number of significant miRNAs and the average variance explained by each disease feature is provided in Figure 2 .
INSS tumor stage explains on average 33.1% of the variance in this serum miRNA dataset. Ten miRNAs were identified as being strongly significantly affected by tumor stage. The average level of significance was P-value < 0.0001 (range: 3.65 x 10 -2 -3.19
x 10 -11 ). Overall survival status (alive or dead of disease) explained an average 25.9% of the variance. Eight miRNAs were identified with an average significance of P-value < 0.05 (range: 3.58 x 10 -2 -5.88 x 10 -3 ). MYCN copy number status and age at diagnosis were responsible for 24.9% and 19.0% of the expression variance, respectively, with an average significance of P-value <0.01 and <0.05, respectively. The number of miRNAs to be significantly influenced by MYCN status or age at diagnosis were 4 and 3, respectively.
None of the identified miRNAs were significantly influenced by two or more disease characteristics. Based on the overall percentage of variance explained and the average level of significance for the identified sets of miRNAs for each disease feature, we concluded that INSS tumor stage had the largest impact on circulating serum miRNA levels.
Identification of serum miRNAs as potential markers for disease burden
Mann-Whitney U test was used to select differentially expressed miRNAs between serum from patients with metastatic disease (stage 4 tumors) and serum from patients with localized disease (stage 1 and stage 2 tumors)
The analysis revealed 327 differentially expressed miRNAs (after correction for multipletesting). 184 and 143 miRNAs were more abundant in serum from metastatic and localized disease, respectively ( Figure 3a ). The magnitude of the differences was much larger for miRNAs circulating in metastatic serum samples ( Figure 3b ). In fact, metastatic serum revealed 10 miRNAs with minimal fold-changes higher than 2 ∆Cq units (~4-fold difference), while the maximum fold-change in serum from localized disease was lower than 2 ∆Cq units.
Interestingly, 9 out of the top 10 differential miRNAs were also put forward by the GAM analysis. These overlapping miRNAs were miR-873-3p, miR-149-5p, miR-124-3p, miR-218-5p, miR-490-5p, miR-323a-3p, miR-10b-3p, miR-375, and miR-129-5p ( Figure 3c ).
We further evaluated the serum levels of the 9 overlapping miRNAs in patients stratified according to INSS tumor stage. Average miRNA abundance was calculated per sample, samples were grouped per stage and depicted by a boxplot in Figure 3d .
A proportional increase of miRNA levels in serum from stage 1 to stage 4 patients was observed. Analysis of variance (Anova-test) was used to quantify the significance of the difference between stage groups. This analysis revealed a significant P-value of 2.0 x 10 -16 . All differences were significant except for the differences between stage 1 and 2 tumors, and stage 4S and all other tumor stages.
Even though we would label the selected miRNAs as being indicators of metastatic tumor load (stage 4 disease) there is a discrepancy with respect to how the miRNAs behave in serum from stage 4S patients. Stage 4S patients have a particular pattern of metastatic disease with good outcome due to spontaneous regression; yet the expression of the selected set of 9 miRNAs is not significantly different from the localized tumor stages. This may be due to the fact that this cohort only contained a limited number of samples. Alternatively, it may reflect the difference in biology between stage 4 and 4S tumors, which may result in a different miRNA signature in patient serum samples. Based on these results, we assume that the identified set of miRNAs qualify as candidate markers of metastatic, non-stage 4S disease (hereafter referred to as markers for metastatic disease).
Validation of serum miRNA markers for metastatic disease in independent patient cohort
In order to evaluate the robustness of the identified markers for metastatic disease, we measured all 743 microRNAs in an independent cohort consisting of sera from 54 neuroblastoma patients.
There is a significantly positive correlation of localized versus metastatic (stage 4) fold change abundance between samples from the first and the second cohort (Pearson's r = 0.7, P<0.001). If only differential miRNAs between localized and metastatic disease are taken into account, the correlation between the two independent sample cohorts is even higher (Pearson's r = 0.91, P<0.001).
In Figure 4a , a distribution of abundance fold changes is shown for localized versus metastatic disease. Seven of the 9 miRNAs identified on the first cohort have a four-fold abundance difference (2 log2 units) in the second sample cohort as well. The remaining two miRNAs show fold differences larger than 2.5 (1.4 log2 units).
A proportional increase in the average expression from the 9 miRNAs from stage 1 to stage 4 was confirmed in the second cohort ( Figure 4b ). An ANOVA test revealed a significant P-value of 5.8 x 10 -14 . All differences between stage 4 samples and samples from other tumor stages were significant (P-value < 0.01). In Figure 4c , the ability of the 9-miRNA set to classify the independent cohort into localized and metastatic disease is shown.
Serum microRNA markers for metastatic disease are specific for neuroblastoma
We further evaluated the specificity of the selected set of 9 miRNAs in serum pools from healthy children and other pediatric cancer entities (sarcoma, nephroblastoma, and rhabdomyosarcoma), as depicted in Figure 5a and 5b. Low to absent levels were observed in healthy serum. When compared to serum from other pediatric cancer entities, expression levels for 8 out of 9 miRNAs were higher in neuroblastoma serum than in the pools from other pediatric cancer entities.
These results suggest that the increased levels of the identified set of miRNAs in serum from children with neuroblastoma is likely caused by the presence of neuroblastoma tumor cells in the patient's body.
Proportional increase of metastatic disease miRNA markers in serum from mice engrafted with human neuroblastoma cells
To evaluate to what extent tumor volume may impact the levels of miRNA markers for metastatic, we engrafted four-to-six-week-old immunodeficient mice with human luciferase-positive SH-SY5Y neuroblastoma cells. Small RNA sequencing was performed on serum samples collected 6 days before engraftment, and 11 days and 25 days after engraftment. Abundance levels of the selected set of 9 miRNAs was evaluated, in order to determine how the tumor graft impacted circulation of these miRNAs in murine serum. Significantly increased miRNA levels over time were observed for the selected miRNAs ( Figure 6a and 6b). Of note, for miR-873-3p, the only miRNA that is not conserved between human and mouse, no detection was found prior to engraftment, with increasing levels 11 and 25 days post engraftment ( Figure 6c ).
The higher detection levels of the selected miRNAs between 11 and 25 days post engraftment were associated with substantial tumor growth as evidenced by increased luciferase bioluminescence ( Figure 6d ).
These findings indicate that an increase in tumor volume results in increased abundance of the 9 miRNAs in murine serum; at least one of the miRNAs (human specific miR-873-3p) must directly originate from the growing human tumor in the immunodeficient mice.
Serum markers for metastatic disease are high but non-differential in primary tumors Two public datasets of miRNA expression in fresh-frozen diagnostic neuroblastoma tumors were used to evaluate expression of the serum markers for metastatic disease in the tumor. The tumor expression datasets were generated using different miRNA expression profiling technologies than used in the present study: (i) stem-loop RT-qPCR miRNA expression method (Life Technologies), as described in Mestdagh et al. (2008) and (ii) small RNA sequencing as described in Schulte et al. (2010) . [8, 9] There were 201 microRNAs measured in common between our serum dataset and the stem-loop RT-qPCR tumor dataset, including 6 of the 9 serum markers for metastatic disease. These 6 miRNAs were among the top 55% miRNAs with the highest expression In the small RNA sequencing dataset, there were 5 patients with metastatic (stage 4) disease and fatal outcome and 5 patients with localized disease (stage 1) and favorable outcome. All 9 serum markers for disease burden were present in the tumor dataset. These miRNAs were among the top 54% miRNAs with highest expression in the tumor (Figure 7c ). No positive correlation was found between serum and tumor microRNA fold changes (Pearson = -0.13, P-value = 0.01) ( Figure 7d ). Only 2/9 miRNAs (miR-129-5p and miR-149-5p) showed a significantly differential expression between metastatic and localized disease in the tumor dataset. Again, while in serum these miRNAs are more abundant in metastatic disease, in tumor they were found to be higher expressed in localized disease.
Discussion
In this study, the abundance levels of 743 human miRNAs were evaluated in 185 diagnostic serum samples from 2 neuroblastoma patient cohorts. The association between circulating miRNA abundance variance and patient characteristics in the 1 st cohort revealed that tumor stage had the strongest impact on miRNA levels. By taking the overlap from the differential abundance analysis when comparing metastatic stage 4 and localized stages 1 and 2 disease and the outcome of the variance modeling, a core set of 9 miRNAs was defined. These miRNAs were highly abundant in serum from patients with metastatic disease in both tested patient cohorts. Evaluation of the selected set of 9 miRNAs in serum from stage 1,2, 3, 4 and 4S disease showed that the more the disease is spread throughout the body, the higher the levels of the selected miRNAs in serum are. This significant association to tumor stage was confirmed in both patient cohorts and we therefore decided to label this set of miRNAs as potential circulating biomarkers for metastatic disease in neuroblastoma.
To evaluate to what extent tumor load could influence circulating miRNA levels, we measured their abundance in serum from mice orthotopically engrafted with human neuroblastoma cells. A clear increase of the core set of 9 serum miRNA levels was observed 11 days and 25 days after orthotopic injection. Interestingly, there was one non-conserved (human-specific) miRNA which was only detected in murine serum after human neuroblastoma engraftment (first time point, 11 days after engraftment), with even more pronounced abundance two weeks later (25 days after engraftment).
Furthermore, the increased levels of the core set of 9 miRNAs in murine serum were accompanied by substantial growth of the human tumor in the murine host. Not only do these findings show that the increased levels of the core set of miRNAs in serum is triggered by the growing neuroblastoma tumor, but they also provide clear evidence that at least one of these miRNAs is derived from the tumor tissue itself.
Comparison of neuroblastoma serum with serum from healthy children or from children with other cancer types showed that the core set of miRNAs is primarily detected at high levels in neuroblastoma serum, indicating that these miRNAs may be specific to neuroblastoma disease. In a similar study, performed by Murray et al. (2015) , [6] 5 miRNAs were shown to be specifically abundant in serum from MYCN-amplified highrisk neuroblastoma compared to serum from non-MYCN-amplified low-risk neuroblastoma and 9 other pediatric cancer entities. Three of these miRNAs (miR-124-3p, miR-218-5p and miR-490-5p) were also part of the core set of miRNAs identified in the present study. These confirmatory results show that the findings in our study are robust and highlight the potential of using serum miRNAs in future clinical practice since their abundance may be reliably measured independently from sample processing methodologies and miRNA profiling technologies.
In order to assess whether the circulating biomarker miRNAs are overexpressed in metastatic tumors compared to localized neuroblastoma, we evaluated their expression in two public datasets from diagnostic primary neuroblastoma samplesone established using stem-loom RT-qPCR and the other by deep sequencing of small RNAs. The comparison of abundance differences between serum and primary tumor from metastatic versus localized disease showed a reproducible lack of correlation. There were two commonly differentially expressed miRNAs between metastatic and localized disease: miR-129-p and miR-149-5p. However, in each tumor tissue dataset these miRNAs were significantly higher expressed in localized disease compared to metastatic disease, while the inverse holds true for their circulating levels in the serum.
This finding strongly suggests that the miRNA levels in serum are not upregulated due to differential expression in the tumor, but are likely proportional with tumor volume, and as such reflect disease burden and metastatic status. The fact that these miRNAs were among the most abundant miRNAs in the primary tumor further supports this.
With the present study, we provide unique first insights into the poorly understood mechanisms behind serum miRNA levels and its relation to tumor miRNA expression. In summary, we have identified 9 miRNAs and convincingly demonstrated that their elevated levels in serum are correlated to metastatic neuroblastoma disease in human samples and tumor volume in serum samples from murine xenografts. Further studies are required in order to evaluate the utility of these miRNAs as potential biomarkers for disease burden in a longitudinal disease monitoring or treatment efficacy study design. The same approach was used for preparation of three additional pools from diagnostic serum from the other pediatric cancer entities and healthy controls. For reverse transcription (miScript II RT kit, Qiagen), 1.5 µl RNA was mixed with 1 µl reverse transcriptase, 2 µl RT buffer, 1 µl nucleic acid mix and 4.5 µl RNase-free water. Samples were incubated for 60 minutes at 37 °C and 5 minutes at 95 °C.
Patient demographics
RNA isolation, reverse transcription and RT-qPCR reaction
2 µl of the RT product was diluted 22-fold with 42 µl nuclease-free water and used for quantification of synthetic spike-in RNA molecules: cel-miR-39-3p and miRTC in 10 µl qPCR reactions. To this purpose, 2 µl of the diluted RT product was mixed with 5 µl SYBR Green PCR mix, 1 µl universal primer, 1 µl miRNA specific primer and 1 µl RNase-free.
Samples were incubated at 95 °C for 15 minutes, followed by 40 cycles of denaturation (15 seconds at 94 °C) annealing (30 seconds at 55 °C) and extension (30 seconds at 70 °C).
For the preamplification reaction (miScript PreAMP PCR Kit, Qiagen), 5 µl of 5-fold diluted RT product was mixed with 5 µl preamp buffer, 2 µl DNA polymerase, 5 µl target specific assay pool, 1 µl universal primer mix and 7 µl RNase-free water to obtain a 25 µl preamplification reaction. Samples were incubated at 95 °C for 15 minutes, followed by two cycles of denaturation (30 seconds at 94 °C) annealing (60 seconds at 55 °C) and extension (60 seconds at 70 °C) and 10 additional cycles of denaturation (30 seconds at 94 °C) and one-step annealing/extension (3 minutes at 60 °C). 100 µl nuclease-free water was added to the 25 µl preamplification product in order to obtain a 5-fold dilution.
For miRNA quantification on the preamplified product, 5 µl qPCR reactions were prepared for each miRNA and each sample. 384-well plates, pre-spotted with 1X miRNA qPCR primer assays were used. qPCR mix was prepared for each multi-well plate by mixing 1025 µl SYBR Green PCR mix, 205 µl universal primer mix, 50 µl preamplified template cDNA, 770 µl nuclease-free water and dispensed by a Tecan (2014). [11] In the current study, two neuroblastoma sample pools were used instead of technical replicate samples. The fraction of single positive results was reduced by 95% at Cq-value 29, which was chosen as Cq detection cut-off.
Collection and processing of murine serum samples
Expression data from murine serum was obtained from Van Goethem et al. (2017) [12] .
In brief, miRNA expression profiles were generated through small RNA sequencing of serum samples from female mice bearing orthotopic neuroblastoma xenografts. 1 x 10 6 human luciferase-SH-SY5Y neuroblastoma cells were surgically implanted in athymic immunodeficient NCr nude mice. Tumor size was assessed 14 days and 23 days after injection of neuroblastoma cells, by measurement of luciferase intensity. 100 µl blood was collected, 6 days before, 11 days after and 25 days after tumor cell injection in serum BD Vacutainer tubes. 50 µl of the resulting serum was used for RNA isolation with the miRNeasy serum/plasma kit (Qiagen). Subsequently, tRNA fragment depletion was performed as described in Van Goethem et al. (2016) . [13] The tRNA depleted RNA samples were then suspended in 7.5 µl RNAse-free water and used for small RNA library preparation by TruSeq small RNA library preparation kit v2 (Illumina). Library size selection was performed on a Pippin Prep (Sage Science) device with a specified collection size range of 125-153 bp. Libraries were further purified and concentrated by precipitation and quantified using qPCR. Subsequently, equimolar library pools were prepared, and further diluted to 4 nM. The pooled library was sequenced at a final concentration of 1.2 pM on a NextSeq 500 using high output v2 kits (single-end, 75 cycles, Illumina). Quantification of small RNAs was done using Cobra, Biogazelle, Ghent).
Preprocessing and data analysis
In order to define the neuroblastoma serum miRNome, pairwise comparisons of miRNA expression of the three serum pools was performed to select miRNAs detected in at least one of the serum pools based on three selection criteria. First, miRNAs with ∆Cq larger than 1.5 between two pools were selected (303 miRNAs). Second, miRNAs
showing Cq-values below 27 in one sample and an absent signal (Cq > 29) in the other sample were selected (90 miRNAs). The final selection criterion was based on detection (Cq < 28) in the high-risk serum pools (358). This resulted in a total of 751 unique miRNAs that were subsequently profiled in a first patient cohort of 131 individual serum samples.
A second patient cohort containing 54 neuroblastoma serum samples was independently collected at a later stage of the study and processed by a different batch of miRNA expression profiling reagents.
A threshold Cq-value of 29 was determined based on the evaluation of single positive signals obtained from replicate miRNA expression data, as described in Mestdagh et al. (2014) . [11] After removal of Cq-values above 29 cycles, miRNAs with missing values in more than 75% (an empirically chosen threshold) of the samples were excluded from the dataset. This led to exclusion of 8 miRNAs.
Raw Cq data were normalized as described in D'haene et al., (2012) . [14] Briefly, the arithmetic mean Cq for each miRNA across all samples was determined and based on 9 miRNAs with at least four-fold higher abundance in serum from metastatic patients. d) Boxplot of average miRNA expression for the selected set of 9 miRNAs in serum from stage 1, 2, 3, 4 and 4S patients. Figure 6 : a) Average miRNA abundance of 9 metastatic miRNAs in murine serum from mice, 6 days before engraftment, 11 days and 25 days after engraftment with human neuroblastoma tissue. b) Expression of the individual miRNAs in murine serum from mice 6 days before engraftment, 11 days and 25 days after engraftment.
(i) Non-conserved miRNA between mouse and human. c) Relative abundance of human miRNA miR-873-3p in murine serum 6 days before engraftment, 11 days and 25 days after engraftment. d) Luciferase fluorescence assessment of tumor volume, 14 days and 23 days after engraftment. 
